Amedisys Reports Second Quarter 2020 Financial Results - Reissues 2020 Guidance

Rhea-AI Summary

Amedisys, Inc. (NASDAQ: AMED) reported Q2 2020 net service revenue of $485 million, down $8 million from $493 million in 2019. Net income increased to $34.7 million ($1.04 per diluted share) from $33.7 million ($1.02) year-over-year. Year-to-date revenue rose to $976.7 million, with net income of $66.5 million ($2.00 per diluted share), up from $65 million ($1.98). The company reaffirmed its 2020 guidance, anticipating annual net revenue between $2.040 billion and $2.070 billion and adjusted EBITDA of $245 million to $255 million. CEO Paul B. Kusserow highlighted company resilience during the COVID-19 pandemic.

Positive

• Net income for Q2 2020 increased to $34.7 million from $33.7 million in 2019.
• Adjusted net income attributable to Amedisys increased to $44.5 million, up from $39.9 million in 2019.
• Year-to-date net service revenue rose to $976.7 million, an increase of $16.4 million year-over-year.
• Company reaffirmed 2020 guidance with expected net service revenue between $2.040 billion and $2.070 billion.

Negative

• Q2 net service revenue decreased by $8 million compared to 2019.
• Adjusted net service revenue fell to $485 million from $498.5 million in 2019.

BATON ROUGE, La., July 28, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month period ended June 30, 2020.

Three-Month Periods Ended June 30, 2020 and 2019

• Net service revenue decreased $8.0 million to $485.0 million compared to $493.0 million in 2019.
• Net income attributable to Amedisys, Inc. of $34.7 million compared to $33.7 million in 2019.
• Net income attributable to Amedisys, Inc. per diluted share of $1.04 compared to $1.02 in 2019.

Adjusted Quarterly Results*

• Adjusted EBITDA of $66.4 million compared to $61.4 million in 2019.
• Adjusted net service revenue of $485.0 million compared to $498.5 million in 2019.
• Adjusted net income attributable to Amedisys, Inc. of $44.5 million compared to $39.9 million in 2019.
• Adjusted net income attributable to Amedisys, Inc. per diluted share of $1.34 compared to $1.21 in 2019.

Six-Month Periods Ended June 30, 2020 and 2019

• Net service revenue increased $16.4 million to $976.7 million compared to $960.3 million in 2019.
• Net income attributable to Amedisys, Inc. of $66.5 million compared to $65.0 million in 2019.
• Net income attributable to Amedisys, Inc. per diluted share of $2.00 compared to $1.98 in 2019.

Adjusted Year to Date Results*

• Adjusted EBITDA of $119.7 million compared to $116.2 million in 2019.
• Adjusted net service revenue of $976.7 million compared to $966.3 million in 2019.
• Adjusted net income attributable to Amedisys, Inc. of $79.3 million compared to $76.3 million in 2019.
• Adjusted net income attributable to Amedisys, Inc. per diluted share of $2.39 compared to $2.32 in 2019.

* See pages 13-15 for the definition and reconciliations of non-GAAP financial measures to GAAP measures.

Paul B. Kusserow, President and Chief Executive Officer stated, “I am very proud of our second quarter results which have allowed us to reissue our full year 2020 guidance ranges, but once again, more proud of our employees that delivered these results during such a momentous and unprecedented time in our nation’s history. Our front-line heroes continue to provide the highest quality care to our patients, wherever they call home even in the face of this Public Health Emergency. They have adapted to our COVID-19 policies and procedures, utilized PPE to protect both themselves and our patients, quickly implemented telehealth for additional patient touch points and have gone above and beyond to be great partners to our referral sources. The pandemic continues to highlight the importance of caring for people in their homes, wherever they call home, and as such has positioned Amedisys for continued growth in the future. A special thank you to all our essential healthcare workers - you are true heroes and none of this would be possible without you.”

2020 Guidance

• Net service revenue is anticipated to be in the range of $2.040 billion to $2.070 billion.
• Adjusted EBITDA is anticipated to be in the range of $245 million to $255 million.
• Adjusted diluted earnings per share is anticipated to be in the range of $4.84 to $5.06 based on an estimated 33.4 million shares outstanding.

This guidance excludes the effects of any future acquisitions, if any are made.

We urge caution in considering the current trends and 2020 guidance disclosed in this press release. The home health, hospice and personal care industries are highly competitive and subject to intensive regulations, and trends are subject to numerous factors, risks, and uncertainties, some of which are referenced in the cautionary language below and others that are described more fully in our reports filed with the Securities and Exchange Commission (“SEC”) including our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, subsequent Quarterly Reports on Form 10-Q, and current reports on Form 8-K which can be found on the SEC’s internet website, http://www.sec.gov, and our internet website, http://www.amedisys.com. 

Earnings Call and Webcast Information

Amedisys will host a conference call on Wednesday, July 29, 2020, at 11:00 a.m. ET to discuss its second quarter results. To participate on the conference call, please call before 11:00 a.m. ET to either (877) 524-8416 (Toll-Free) or (412) 902-1028 (Toll). A replay of the conference call will be available through August 29, 2020 by dialing (877) 660-6853 (Toll-Free) or (201) 612-7415 (Toll) and entering conference ID #13706583.

A live webcast of the call will be accessible through our website on our Investor Relations section at the following web address: http://investors.amedisys.com.

Non-GAAP Financial Measures

This press release includes reconciliations of the most comparable financial measures calculated and presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”) to non-GAAP financial measures. The non-GAAP financial measures as defined under SEC rules are as follows: (1) adjusted EBITDA, defined as net income attributable to Amedisys, Inc. before provision for income taxes, net interest expense and depreciation and amortization, excluding certain items; (2) adjusted net service revenue, defined as net service revenue excluding certain items; (3) adjusted other operating income, defined as other operating income excluding certain items; (4) adjusted net income attributable to Amedisys, Inc., defined as net income attributable to Amedisys, Inc. excluding certain items; and (5) adjusted net income attributable to Amedisys, Inc. per diluted share, defined as net income attributable to Amedisys, Inc. common stockholders per diluted share excluding certain items. Management believes that these non-GAAP financial measures, when reviewed in conjunction with GAAP financial measures, are useful gauges of our current performance and are also included in internal management reporting. These non-GAAP financial measures should be considered in addition to, and not more meaningful than or as an alternative to the GAAP financial measures presented in this earnings release and the company’s financial statements. Non-GAAP measures as presented herein may not be comparable to similarly titled measures reported by other companies since not all companies calculate these non-GAAP measures consistently.

Additional information

Amedisys, Inc. (the “Company”) is a leading healthcare at home company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering our patients to manage a chronic disease; or hospice care at the end of life. More than 2,600 hospitals and 67,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With more than 21,000 employees in 526 care centers within 39 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 415,000 patients and clients in need every year. For more information about the Company, please visit: www.amedisys.com. 

We use our website as a channel of distribution for important company information. Important information, including press releases, investor presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled “Investors” on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website.

Forward-Looking Statements

When included in this press release, words like “believes,” “belief,” “expects,” “strategy,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “could,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: the impact of the novel coronavirus pandemic (“COVID-19”), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations, changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis, changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, competition in the healthcare industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to consistently provide high-quality care, our ability to attract and retain qualified personnel, our ability to keep our patients and employees safe, changes in payments and covered services by federal and state governments, future cost containment initiatives undertaken by third-party payors, our access to financing, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disaster, acts of terrorism, widespread protest or civil unrest, our ability to integrate, manage and keep our information systems secure, our ability to realize the anticipated benefits of acquisitions and changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

Contact:	Investor Contact:		Media Contact:
	Amedisys, Inc.		Amedisys, Inc.
	Nick Muscato		Kendra Kimmons
	Vice President, Strategic Finance		Vice President, Marketing & Communications
	(855) 259-2046		(225) 299-3720
	IR@amedisys.com		kendra.kimmons@amedisys.com

AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands, except per share data)
(Unaudited)

	For the Three-Month Periods Ended June 30,								For the Six-Month Periods Ended June 30,
		2020				2019				2020				2019
Net service revenue	$	485,059			$	492,984			$	976,744			$	960,324
Other operating income		22,780				—				22,780				—
Cost of service, excluding depreciation and amortization		295,228				290,752				580,965				566,026
General and administrative expenses:
Salaries and benefits		105,617				98,356				207,183				193,186
Non-cash compensation		6,725				5,538				12,634				12,153
Other		44,003				48,408				93,268				91,810
Depreciation and amortization		6,334				5,179				11,672				8,074
Operating expenses		457,907				448,233				905,722				871,249
Operating income		49,932				44,751				93,802				89,075
Other income (expense):
Interest income		214				20				227				44
Interest expense		(2,752	)			(4,332	)			(5,983	)			(7,681	)
Equity in earnings from equity method investments		487				3,716				964				4,932
Miscellaneous, net		(2,703	)			193				(2,440	)			429
Total other expense, net		(4,754	)			(403	)			(7,232	)			(2,276	)
Income before income taxes		45,178				44,348				86,570				86,799
Income tax expense		(10,031	)			(10,308	)			(19,377	)			(21,186	)
Net income		35,147				34,040				67,193				65,613
Net income attributable to noncontrolling interests		(473	)			(298	)			(717	)			(567	)
Net income attributable to Amedisys, Inc	$	34,674			$	33,742			$	66,476			$	65,046
Basic earnings per common share:
Net income attributable to Amedisys, Inc. common stockholders	$	1.07			$	1.05			$	2.05			$	2.03
Weighted average shares outstanding		32,412				32,075				32,371				32,038
Diluted earnings per common share:
Net income attributable to Amedisys, Inc. common stockholders	$	1.04			$	1.02			$	2.00			$	1.98
Weighted average shares outstanding		33,285				32,933				33,259				32,913

AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except share data)

	June 30, 2020 (unaudited)				December 31, 2019
ASSETS
Current assets:
Cash and cash equivalents	$	177,278			$	30,294
Restricted cash		3,049				66,196
Patient accounts receivable		249,030				237,596
Prepaid expenses		10,788				8,243
Other current assets		9,395				8,225
Total current assets		449,540				350,554
Property and equipment, net of accumulated depreciation of $100,963 and $96,137		25,007				28,113
Operating lease right of use assets		92,904				84,791
Goodwill		937,088				658,500
Intangible assets, net of accumulated amortization of $12,649 and $7,044		81,813				64,748
Deferred income taxes		25,463				21,427
Other assets		33,673				54,612
Total assets	$	1,645,488			$	1,262,745
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable	$	33,383			$	31,259
Payroll and employee benefits		128,275				120,877
Accrued expenses		169,722				137,111
Provider relief fund advance		70,000				—
Current portion of long-term obligations		10,718				9,927
Current portion of operating lease liabilities		29,950				27,769
Total current liabilities		442,048				326,943
Long-term obligations, less current portion		392,713				232,256
Operating lease liabilities, less current portion		61,611				56,128
Other long-term obligations		26,857				5,905
Total liabilities		923,229				621,232
Equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding		—				—
Common stock, $0.001 par value, 60,000,000 shares authorized; 36,831,298 and 36,638,021 shares issued; and 32,442,719 and 32,284,051 shares outstanding		37				37
Additional paid-in capital		665,580				645,256
Treasury stock, at cost 4,388,579 and 4,353,970 shares of common stock		(257,625	)			(251,241	)
Accumulated other comprehensive income		—				15
Retained earnings		312,859				246,383
Total Amedisys, Inc. stockholders’ equity		720,851				640,450
Noncontrolling interests		1,408				1,063
Total equity		722,259				641,513
Total liabilities and equity	$	1,645,488			$	1,262,745

AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS AND DAYS REVENUE OUTSTANDING
(Amounts in thousands, except statistical information)
(Unaudited)

	For the Three-Month Periods Ended June 30,								For the Six-Month Periods Ended June 30,
		2020				2019				2020				2019
Cash Flows from Operating Activities:
Net income	$	35,147			$	34,040			$	67,193			$	65,613
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		6,334				5,179				11,672				8,074
Non-cash compensation		6,725				5,538				12,634				12,153
Non-cash 401(k) employer match		—				2,307				—				4,686
Amortization and impairment of operating lease right of use assets		9,500				9,150				18,558				17,495
(Gain) loss on disposal of property and equipment		(149	)			2				(94	)			(2	)
Loss on sale of equity method investment		2,980				—				2,980				—
Write-off of other comprehensive income		—				—				(15	)			—
Deferred income taxes		(5,264	)			2,606				(4,036	)			5,875
Equity in earnings from equity method investments		(487	)			(3,716	)			(964	)			(4,932	)
Amortization of deferred debt issuance costs/debt discount		217				220				437				433
Return on equity investment		375				117				2,744				842
Changes in operating assets and liabilities, net of impact of acquisitions:
Patient accounts receivable		34,456				(1,832	)			8,997				(24,165	)
Other current assets		2,287				2,292				(3,469	)			(8,343	)
Other assets		(1,092	)			282				(675	)			(56	)
Accounts payable		(3,779	)			1,665				(6,452	)			(9,475	)
Accrued expenses		38,326				10,424				27,990				29,262
Other long-term obligations		17,686				(37	)			20,746				(181	)
Operating lease liabilities		(8,233	)			(8,061	)			(16,365	)			(16,200	)
Operating lease right of use assets		(1,107	)			(910	)			(1,924	)			(1,754	)
Net cash provided by operating activities		133,922				59,266				139,957				79,325
Cash Flows from Investing Activities:
Proceeds from sale of deferred compensation plan assets		5				5				21				213
Proceeds from the sale of property and equipment		68				81				80				146
Purchases of property and equipment		(267	)			(1,495	)			(1,701	)			(2,693	)
Investments in equity method investees		(875	)			(90	)			(875	)			(210	)
Proceeds from sale of equity method investment		17,876				—				17,876				—
Acquisitions of businesses, net of cash acquired		(230,374	)			(17,547	)			(299,723	)			(345,414	)
Net cash used in investing activities		(213,567	)			(19,046	)			(284,322	)			(347,958	)
Cash Flows from Financing Activities:
Proceeds from issuance of stock upon exercise of stock options		1,763				987				2,947				1,343
Proceeds from issuance of stock to employee stock purchase plan		826				752				1,686				1,534
Shares withheld to pay taxes on non-cash compensation		(2,334	)			(1,802	)			(6,384	)			(4,490	)
Noncontrolling interest distribution		(12	)			(91	)			(372	)			(457	)
Proceeds from borrowings under term loan		—				—				—				175,000
Proceeds from borrowings under revolving line of credit		237,000				23,000				424,500				184,500
Repayments of borrowings under revolving line of credit		(222,000	)			(58,000	)			(259,500	)			(92,000	)
Principal payments of long-term obligations		(3,083	)			(1,718	)			(4,675	)			(2,277	)
Debt issuance costs		—				—				—				(847	)
Provider relief fund advance		70,000				—				70,000				—
Net cash provided by (used in) financing activities		82,160				(36,872	)			228,202				262,306
Net increase (decrease) in cash, cash equivalents and restricted cash		2,515				3,348				83,837				(6,327	)
Cash, cash equivalents and restricted cash at beginning of period		177,812				10,554				96,490				20,229
Cash, cash equivalents and restricted cash at end of period	$	180,327			$	13,902			$	180,327			$	13,902

Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	$	1,537			$	3,462			$	3,292			$	4,187
Cash paid for income taxes, net of refunds received	$	2,881			$	7,445			$	8,153			$	7,849
Cash paid for operating lease liabilities	$	9,340			$	8,971			$	18,289			$	17,954
Cash paid for finance lease liabilities	$	487			$	408			$	986			$	792
Supplemental Disclosures of Non-Cash Activity:
Right of use assets obtained in exchange for operating lease liabilities	$	12,454			$	10,488			$	18,891			$	102,231
Right of use assets obtained in exchange for finance lease liabilities	$	233			$	998			$	487			$	1,806
Reductions to right of use assets resulting from reductions to operating lease liabilities	$	248			$	286			$	407			$	911
Days revenue outstanding (1)		42.0				41.1				42.0				41.1

(1) Our calculation of days revenue outstanding at June 30, 2020 and 2019 is derived by dividing our ending patient accounts receivable by our average daily patient revenue for the three-month periods ended June 30, 2020 and 2019, respectively.

AMEDISYS, INC. AND SUBSIDIARIES
SEGMENT INFORMATION
(Amounts in millions, except statistical information)
(Unaudited)

Segment Information - Home Health

	For the Three-Month Periods Ended June 30,
		2020				2019
Financial Information (in millions):
Medicare	$	192.9			$	219.1
Non-Medicare		97.3				99.5
Net service revenue		290.2				318.6
Other operating income		15.1				—
Cost of service		184.0				187.8
Gross margin		121.3				130.8
Other operating expenses		73.1				75.1
Operating income	$	48.2			$	55.7
Same Store Growth (1):
Medicare revenue		(12	%)			6	%
Non-Medicare revenue		(2	%)			17	%
Total admissions		(9	%)			7	%
Total volume (2)		(2	%)			6	%
Key Statistical Data - Total (3):
Admissions		74,327				81,763
Recertifications		47,628				43,361
Total volume		121,955				125,124
Medicare completed episodes (6)		68,660				77,939
Average Medicare revenue per completed episode (4) (6)	$	2,818			$	2,885
Medicare visits per completed episode (5) (6)		15.4				17.3
Visiting Clinician Cost per Visit	$	93.17			$	81.97
Clinical Manager Cost per Visit	$	9.42			$	7.65
Total Cost per Visit	$	102.59			$	89.62
Visits		1,793,652				2,096,486

	For the Six-Month Periods Ended June 30,
		2020				2019
Financial Information (in millions):
Medicare	$	396.8			$	432.5
Non-Medicare		197.0				196.2
Net service revenue		593.8				628.7
Other operating income		15.1				—
Cost of service		363.8				373.5
Gross margin		245.1				255.2
Other operating expenses		149.8				147.5
Operating income	$	95.3			$	107.7
Same Store Growth (1):
Medicare revenue		(8	%)			5	%
Non-Medicare revenue		—	%			20	%
Total admissions		(3	%)			7	%
Total volume (2)		(1	%)			6	%
Key Statistical Data - Total (3):
Admissions		160,302				165,732
Recertifications		88,169				85,156
Total volume		248,471				250,888
Medicare completed episodes (6)		144,296				153,422
Average Medicare revenue per completed episode (4) (6)	$	2,774			$	2,862
Medicare visits per completed episode (5) (6)		15.6				17.2
Visiting Clinician Cost per Visit	$	88.41			$	81.51
Clinical Manager Cost per Visit	$	9.19			$	7.83
Total Cost per Visit	$	97.60			$	89.34
Visits		3,727,097				4,181,574

⁽¹⁾ Same store information represents the percent change in our Medicare, Non-Medicare and Total revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare and Total revenue, admissions or volume of the prior period. Effective July 1, 2019, same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.
⁽²⁾ Total volume includes all admissions and recertifications.
⁽³⁾ Total includes acquisitions and denovos.
⁽⁴⁾ Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care. Average Medicare revenue per completed episode for the three and six-month periods ended June 30, 2020 reflects the suspension of sequestration effective May 1, 2020. Additionally, average Medicare revenue per completed episode for the six-month period ended June 30, 2020 reflects the transition to PDGM during the year and therefore includes reimbursement under both the 60-day episode of care (pre-PDGM) payment rate and the 30-day period of care (PDGM) payment rate.
⁽⁵⁾ Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.
⁽⁶⁾ Prior year amounts have been recast to conform to the current year calculation.

Segment Information - Hospice

	For the Three-Month Periods Ended June 30,
		2020				2019
Financial Information (in millions):
Medicare	$	167.0			$	145.8
Non-Medicare		10.1				7.4
Net service revenue		177.1				153.2
Other operating income		7.2				—
Cost of service		97.2				87.3
Gross margin		87.1				65.9
Other operating expenses		41.4				35.3
Operating income	$	45.7			$	30.6
Same Store Growth (1):
Medicare revenue		4	%			1	%
Hospice admissions		(1	%)			7	%
Average daily census		—	%			5	%
Key Statistical Data - Total (2):
Hospice admissions		11,411				10,430
Average daily census		12,513				11,427
Revenue per day, net	$	155.51			$	147.27
Cost of service per day	$	85.34			$	83.96
Average discharge length of stay		94				98

	For the Six-Month Periods Ended June 30,
		2020				2019
Financial Information (in millions):
Medicare	$	327.5			$	276.5
Non-Medicare		19.0				13.7
Net service revenue		346.5				290.2
Other operating income		7.2				—
Cost of service		189.0				161.4
Gross margin		164.7				128.8
Other operating expenses		80.7				64.7
Operating income	$	84.0			$	64.1
Same Store Growth (1):
Medicare revenue		5	%			5	%
Hospice admissions		—	%			6	%
Average daily census		2	%			7	%
Key Statistical Data - Total (2):
Hospice admissions		22,729				20,141
Average daily census		12,279				10,709
Revenue per day, net	$	155.04			$	149.72
Cost of service per day	$	84.58			$	83.25
Average discharge length of stay		96				98

⁽¹⁾ Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Effective July 1, 2019, same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.
⁽²⁾ Total includes acquisitions and denovos.

Segment Information - Personal Care

	For the Three-Month Periods Ended June 30,
		2020			2019
Financial Information (in millions):
Medicare	$	—		$	—
Non-Medicare		17.7			21.2
Net service revenue		17.7			21.2
Other operating income		0.5			—
Cost of service		14.1			15.6
Gross margin		4.1			5.6
Other operating expenses		3.0			3.2
Operating income	$	1.1		$	2.4
Key Statistical Data - Total (1):
Billable hours		642,720			848,245
Clients served		9,956			12,962
Shifts		282,207			382,287
Revenue per hour	$	27.58		$	25.01
Revenue per shift	$	62.80		$	55.49
Hours per shift		2.3			2.2

	For the Six-Month Periods Ended June 30,
		2020			2019
Financial Information (in millions):
Medicare	$	—		$	—
Non-Medicare		36.4			41.4
Net service revenue		36.4			41.4
Other operating income		0.5			—
Cost of service		28.2			31.1
Gross margin		8.7			10.3
Other operating expenses		6.4			6.4
Operating income	$	2.3		$	3.9
Key Statistical Data - Total (1):
Billable hours		1,394,797			1,681,862
Clients served		12,936			14,687
Shifts		615,671			758,469
Revenue per hour	$	26.12		$	24.60
Revenue per shift	$	59.17		$	54.56
Hours per shift		2.3			2.2

⁽¹⁾ Total includes acquisitions.

Segment Information - Corporate

	For the Three-Month Periods Ended June 30,
		2020			2019
Financial Information (in millions):
Other operating expenses	$	40.3		$	40.2
Depreciation and amortization		4.8			3.7
Total operating expenses	$	45.1		$	43.9

	For the Six-Month Periods Ended June 30,
		2020			2019
Financial Information (in millions):
Other operating expenses	$	79.2		$	81.5
Depreciation and amortization		8.6			5.1
Total operating expenses	$	87.8		$	86.6

AMEDISYS, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES TO GAAP MEASURES
(Amounts in thousands)
(Unaudited)

Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“Adjusted EBITDA”) Reconciliation:

	For the Three- Month Periods Ended June 30,								For the Six- Month Periods Ended June 30,
		2020				2019				2020				2019
Net income attributable to Amedisys, Inc.	$	34,674			$	33,742			$	66,476			$	65,046
Add:
Income tax expense		10,031				10,308				19,377				21,186
Interest expense, net		2,538				4,312				5,756				7,637
Depreciation and amortization		6,334				5,179				11,672				8,074
Certain items (1)		13,313				8,257				17,349				15,171
Interest component of certain items (1)		(446	)			(446	)			(892	)			(887	)
Adjusted EBITDA (2) (7)	$	66,444			$	61,352			$	119,738			$	116,227

Adjusted Net Service Revenue Reconciliation:

	For the Three- Month Periods Ended June 30,						For the Six- Month Periods Ended June 30,
		2020			2019			2020			2019
Net service revenue	$	485,059		$	492,984		$	976,744		$	960,324
Add:
Certain items (1)		—			5,515			—			5,993
Adjusted net service revenue (3) (7)	$	485,059		$	498,499		$	976,744		$	966,317

Adjusted Other Operating Income Reconciliation:

	For the Three- Month Periods Ended June 30,							For the Six- Month Periods Ended June 30,
		2020				2019			2020				2019
Other operating income	$	22,780			$	—		$	22,780			$	—
Add:
Certain items (1)		(22,780	)			—			(22,780	)			—
Adjusted other operating income (4) (7)	$	—			$	—		$	—			$	—

Adjusted Net Income Attributable to Amedisys, Inc Reconciliation:

	For the Three- Month Periods Ended June 30,						For the Six- Month Periods Ended June 30,
		2020			2019			2020			2019
Net income attributable to Amedisys, Inc.	$	34,674		$	33,742		$	66,476		$	65,046
Add:
Certain items (1)		9,852			6,110			12,839			11,226
Adjusted net income attributable to Amedisys, Inc. (5) (7)	$	44,526		$	39,852		$	79,315		$	76,272

Adjusted Net Income Attributable to Amedisys, Inc. per Diluted Share Reconciliation:

	For the Three- Month Periods Ended June 30,						For the Six- Month Periods Ended June 30,
		2020			2019			2020			2019
Net income attributable to Amedisys, Inc. common stockholders per diluted share	$	1.04		$	1.02		$	2.00		$	1.98
Add:
Certain items (1)		0.30			0.19			0.39			0.34
Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share (6) (7)	$	1.34		$	1.21		$	2.39		$	2.32

⁽¹⁾ The following details the certain items for the three and six-month periods ended June 30, 2020 and 2019:

Certain Items:

	For the Three -Month Period Ended June 30, 2020				For the Six-Month Period Ended June 30, 2020
	(Income) Expense				(Income) Expense
Certain Items Impacting Other Operating Income:
CARES Act & State COVID-19 grants	$	(22,780	)		$	(22,780	)
Certain Items Impacting Cost of Service:
COVID-19 costs		21,993				23,010
Severance-reductions in staffing levels		5,183				5,183
Certain Items Impacting Operating Expenses:
Acquisition and integration costs		3,599				5,935
COVID-19 costs		1,051				1,063
Severance-reductions in staffing levels		271				271
Certain Items Impacting Total Other Income (Expense):
Interest component of certain items		446				892
Other (income) expense, net		3,550				3,775
Total	$	13,313			$	17,349
Net of tax		9,852				12,839
Diluted EPS	$	0.30			$	0.39

	For the Three-Month Period Ended June 30, 2019				For the Six-Month Period Ended June 30, 2019
	(Income) Expense				(Income) Expense
Certain Items Impacting Net Service Revenue:
Contingency accrual	$	5,523			$	6,541
Planned closures (8)		(8	)			(548	)
Certain Items Impacting Cost of Service:
Planned closures (8)		313				1,157
Certain Items Impacting Operating Expenses:
Planned closures (8)		69				157
Acquisition and integration costs		4,494				10,252
Legal fees - non-routine		108				(24	)
Certain Items Impacting Total Other Income (Expense):
Interest component of certain items		446				887
Other (income) expense, net		(2,688	)			(3,251	)
Total	$	8,257			$	15,171
Net of tax		6,110				11,226
Diluted EPS	$	0.19			$	0.34

⁽²⁾ Adjusted EBITDA is defined as net income attributable to Amedisys, Inc. before provision for income taxes, net interest expense and depreciation and amortization, excluding certain items as described in footnote 1.
⁽³⁾ Adjusted net service revenue is defined as net service revenue excluding certain items as described in footnote 1.
⁽⁴⁾ Adjusted other operating income is defined as other operating income excluding certain items as described in footnote 1.
⁽⁵⁾ Adjusted net income attributable to Amedisys, Inc. is defined as net income attributable to Amedisys, Inc. calculated in accordance with GAAP excluding certain items as described in footnote 1.
⁽⁶⁾ Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share is defined as diluted income per share calculated in accordance with GAAP excluding the earnings per share effect of certain items as described in footnote 1.
⁽⁷⁾ Adjusted EBITDA, adjusted net service revenue, adjusted other operating income, adjusted net income attributable to Amedisys, Inc. and adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share should not be considered as an alternative to, or more meaningful than, income before income taxes or other measures calculated in accordance with GAAP. These calculations may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate these non-GAAP financial measures in the same manner.
⁽⁸⁾ Planned closures consist of in-patient units acquired from Compassionate Care Hospice whose operations ceased in April 2019.

FAQ

What were Amedisys' Q2 2020 earnings results?

Amedisys reported Q2 2020 net service revenue of $485 million, net income of $34.7 million, and diluted earnings per share of $1.04.

Did Amedisys increase its 2020 revenue guidance?

Yes, Amedisys reaffirmed its 2020 revenue guidance, expecting net service revenue between $2.040 billion and $2.070 billion.

How did Amedisys perform year-to-date in 2020?

As of June 30, 2020, Amedisys reported year-to-date net service revenue of $976.7 million and net income of $66.5 million.

What were the adjusted EBITDA figures for Amedisys in Q2 2020?

Amedisys reported an adjusted EBITDA of $66.4 million for Q2 2020, compared to $61.4 million in Q2 2019.